117 related articles for article (PubMed ID: 8309439)
41. Planar gamma camera quantitation of 123I, 99mTc or 111In in the liver and spleen of an abdominal phantom.
Macey DJ; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 1999 Aug; 14(4):299-306. PubMed ID: 10850316
[TBL] [Abstract][Full Text] [Related]
42. Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies.
Larsson E; Ljungberg M; Strand SE; Jönsson BA
Acta Oncol; 2011 Aug; 50(6):973-80. PubMed ID: 21767199
[TBL] [Abstract][Full Text] [Related]
43. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients.
Koral KF; Zasadny KR; Kessler ML; Luo JQ; Buchbinder SF; Kaminski MS; Francis I; Wahl RL
J Nucl Med; 1994 Oct; 35(10):1714-20. PubMed ID: 7931676
[TBL] [Abstract][Full Text] [Related]
44. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
45. Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios.
van den Abbeele AD; Aaronson RA; Taube RA; Adelstein SJ; Kassis AI
J Nucl Med Allied Sci; 1990; 34(2):94-102. PubMed ID: 2246677
[TBL] [Abstract][Full Text] [Related]
46. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
[TBL] [Abstract][Full Text] [Related]
47. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
48. Validation of an analytical expression for the absorbed dose from a spherical beta source geometry and its application to micrometastatic radionuclide therapy.
Sarfaraz M; Wessels BW
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3020s-3023s. PubMed ID: 10541338
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
50. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
51. Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody.
Erdi AK; Wessels BW; DeJager R; Erdi YE; Atkins FB; Yorke ED; Smith L; Huang E; Smiddy M; Murray J
Cancer; 1994 Feb; 73(3 Suppl):932-44. PubMed ID: 8306282
[TBL] [Abstract][Full Text] [Related]
52. Comparisons of sectioned micro-TLD dose measurements with predicted dose from 131I-labeled antibody.
Langmuir VK; Wessels BW; Mendonca H; Yorke ED; Montilla L
Med Phys; 1992; 19(5):1213-6. PubMed ID: 1435601
[TBL] [Abstract][Full Text] [Related]
53. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.
Breitz HB; Fisher DR; Weiden PL; Durham JS; Ratliff BA; Bjorn MJ; Beaumier PL; Abrams PG
J Nucl Med; 1993 Jun; 34(6):908-17. PubMed ID: 8509857
[TBL] [Abstract][Full Text] [Related]
54. Murine S factors for liver, spleen, and kidney.
Kolbert KS; Watson T; Matei C; Xu S; Koutcher JA; Sgouros G
J Nucl Med; 2003 May; 44(5):784-91. PubMed ID: 12732681
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
56. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
57. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
[TBL] [Abstract][Full Text] [Related]
58. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
[TBL] [Abstract][Full Text] [Related]
59. Model based calculation for effective cancer radioimmunotherapy.
Attard AR; Chappell MJ; Bradwell AR
Br J Radiol; 1995 Jun; 68(810):636-45. PubMed ID: 7627487
[TBL] [Abstract][Full Text] [Related]
60. Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: the potential for toxicity.
Sparks RB; Crowe EA; Wong FC; Toohey RE; Siegel JA
J Nucl Med; 2002 Aug; 43(8):1110-4. PubMed ID: 12163638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
